✨ Your Portfolio is fetched and updated from zerodha.
Mid Pharmaceuticals

Glaxosmithkline Pharmaceuticals Ltd.

GLAXO

Get real time AI alerts about this company on your WhatsApp!
Market Cap
₹49,702 Cr.
P/E
52.30

Glaxosmithkline Pharmaceuticals Ltd.

  • Glaxosmithkline Phar
  • Glenmark Pharma
  • Alkem Laboratories
  • TJI Pharma
FAQs on Glaxosmithkline Pharmaceuticals Ltd. Shareprice

Glaxosmithkline Phar has given better returns compared to its competitors.
Glaxosmithkline Phar has grown at ~16.32% over the last 4yrs while peers have grown at a median rate of 8.91%

Yes, Glaxosmithkline Phar is expensive.
Latest PE of Glaxosmithkline Phar is 57.68, while 3 year average PE is 48.44.
Also latest EV/EBITDA of Glaxosmithkline Phar is 43.49 while 3yr average is 35.56.

View FAQ's On Business
Growth Table
  • Glaxosmithkline Pharmaceuticals Ltd.
  • Glenmark Pharma
  • Alkem Laboratories
Balance Sheet
  • Glaxosmithkline Pharmaceuticals Ltd.
  • Glenmark Pharma
  • Alkem Laboratories
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Glaxosmithkline Pharmaceuticals Ltd.
  • Glenmark Pharma
  • Alkem Laboratories
Cash Flow
  • Glaxosmithkline Pharmaceuticals Ltd.
  • Glenmark Pharma
  • Alkem Laboratories
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Glaxosmithkline Pharmaceuticals Ltd.
  • Glenmark Pharma
  • Alkem Laboratories
Quarterly Results
  • Glaxosmithkline Pharmaceuticals Ltd.
  • Glenmark Pharma
  • Alkem Laboratories
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF
FAQs on Glaxosmithkline Pharmaceuticals Ltd. Financials

Balance sheet of Glaxosmithkline Phar is strong.
It shouldn't have solvency or liquidity issues.

The net debt of Glaxosmithkline Phar is decreasing.
Latest net debt of Glaxosmithkline Phar is -₹2,807.03 Crs as of Mar-25.
This is less than Mar-24 when it was -₹2,126.44 Crs.

Yes, profit is increasing.
The profit of Glaxosmithkline Phar is ₹950 Crs for TTM, ₹928 Crs for Mar 2025 and ₹590 Crs for Mar 2024.

The company seems to pay a good stable dividend.
Glaxosmithkline Phar latest dividend payout ratio is 98.62% and 3yr average dividend payout ratio is 93.09%

Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments

View FAQ's On Shareholding
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech